Small Cell Lung Cancer/Pancreatic Cancer

The goal of this program is to improve utilization of immunotherapy for small cell lung cancer (SCLC) and management of pancreatic cancer. After hearing and assimilating this program, the clinician will be better able to: 1. Follow evidence-based protocols for the management of limitedstage SCLC. 2. Analyze clinical evidence and outcomes of immunotherapy and BiTE therapy 3. Identify common and severe immune-related adverse events following immunotherapy for SCLC. 4. Utilize arterial and venous involvement criteria to classify patients with pancreatic cancer as resectable, borderline resectable, or locally advanced. 5. Recommend appropriate sequencing of neoadjuvant therapy and initial surgery for pancreatic cancer based on tumor biology, performance status, and trial evidence.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.